Topical naphazoline in the treatment of myasthenic blepharoptosis

Yuriko Nagane, Kimiaki Utsugisawa, Shigeaki Suzuki, Masayuki Masuda, Yuko Shimizu, Hiroya Utsumi, Shinichiro Uchiyama, Norihiro Suzuki

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Introduction. When treating ocular myasthenia gravis (MG), the risk/benefit profile of corticosteroids is unclear, and acetylcholinesterase inhibitors are not very effective. We examined the efficacy of topical naphazoline in the treatment of myasthenic blepharoptosis. Methods. Sixty MG patients with blepharoptosis (32 with ocular symptoms only and 28 with mild generalized symptoms) were enrolled in a multicenter open trial of topical naphazoline. The effects were reported by patients via a questionnaire and were also confirmed for each patient at the clinic. Results. Among 70 eyes of 60 patients, 20 eyes (28.6%) of 17 patients (28.3%) exhibited a marked response (full eye opening), and 24 eyes (34.3%) of 20 patients (33.3%) showed a good response (adequate but incomplete eye opening). Topical naphazoline was evaluated as useful in the treatment of myasthenic blepharoptosis by >70% of the patients. Conclusions. Topical naphazoline was found to be an effective supplementary symptomatic treatment for myasthenic blepharoptosis.

Original languageEnglish
Pages (from-to)41-44
Number of pages4
JournalMuscle and Nerve
Volume44
Issue number1
DOIs
Publication statusPublished - 2011 Jul

Fingerprint

Blepharoptosis
Naphazoline
Muscle Weakness
Myasthenia Gravis
Therapeutics
Cholinesterase Inhibitors
Multicenter Studies
Adrenal Cortex Hormones

Keywords

  • Blepharoptosis
  • Eyewash
  • Myasthenia gravis
  • Naphazoline
  • Open trial

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)
  • Physiology

Cite this

Nagane, Y., Utsugisawa, K., Suzuki, S., Masuda, M., Shimizu, Y., Utsumi, H., ... Suzuki, N. (2011). Topical naphazoline in the treatment of myasthenic blepharoptosis. Muscle and Nerve, 44(1), 41-44. https://doi.org/10.1002/mus.22002

Topical naphazoline in the treatment of myasthenic blepharoptosis. / Nagane, Yuriko; Utsugisawa, Kimiaki; Suzuki, Shigeaki; Masuda, Masayuki; Shimizu, Yuko; Utsumi, Hiroya; Uchiyama, Shinichiro; Suzuki, Norihiro.

In: Muscle and Nerve, Vol. 44, No. 1, 07.2011, p. 41-44.

Research output: Contribution to journalArticle

Nagane, Y, Utsugisawa, K, Suzuki, S, Masuda, M, Shimizu, Y, Utsumi, H, Uchiyama, S & Suzuki, N 2011, 'Topical naphazoline in the treatment of myasthenic blepharoptosis', Muscle and Nerve, vol. 44, no. 1, pp. 41-44. https://doi.org/10.1002/mus.22002
Nagane Y, Utsugisawa K, Suzuki S, Masuda M, Shimizu Y, Utsumi H et al. Topical naphazoline in the treatment of myasthenic blepharoptosis. Muscle and Nerve. 2011 Jul;44(1):41-44. https://doi.org/10.1002/mus.22002
Nagane, Yuriko ; Utsugisawa, Kimiaki ; Suzuki, Shigeaki ; Masuda, Masayuki ; Shimizu, Yuko ; Utsumi, Hiroya ; Uchiyama, Shinichiro ; Suzuki, Norihiro. / Topical naphazoline in the treatment of myasthenic blepharoptosis. In: Muscle and Nerve. 2011 ; Vol. 44, No. 1. pp. 41-44.
@article{590ce06adea64464b18c341857fc74f1,
title = "Topical naphazoline in the treatment of myasthenic blepharoptosis",
abstract = "Introduction. When treating ocular myasthenia gravis (MG), the risk/benefit profile of corticosteroids is unclear, and acetylcholinesterase inhibitors are not very effective. We examined the efficacy of topical naphazoline in the treatment of myasthenic blepharoptosis. Methods. Sixty MG patients with blepharoptosis (32 with ocular symptoms only and 28 with mild generalized symptoms) were enrolled in a multicenter open trial of topical naphazoline. The effects were reported by patients via a questionnaire and were also confirmed for each patient at the clinic. Results. Among 70 eyes of 60 patients, 20 eyes (28.6{\%}) of 17 patients (28.3{\%}) exhibited a marked response (full eye opening), and 24 eyes (34.3{\%}) of 20 patients (33.3{\%}) showed a good response (adequate but incomplete eye opening). Topical naphazoline was evaluated as useful in the treatment of myasthenic blepharoptosis by >70{\%} of the patients. Conclusions. Topical naphazoline was found to be an effective supplementary symptomatic treatment for myasthenic blepharoptosis.",
keywords = "Blepharoptosis, Eyewash, Myasthenia gravis, Naphazoline, Open trial",
author = "Yuriko Nagane and Kimiaki Utsugisawa and Shigeaki Suzuki and Masayuki Masuda and Yuko Shimizu and Hiroya Utsumi and Shinichiro Uchiyama and Norihiro Suzuki",
year = "2011",
month = "7",
doi = "10.1002/mus.22002",
language = "English",
volume = "44",
pages = "41--44",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Topical naphazoline in the treatment of myasthenic blepharoptosis

AU - Nagane, Yuriko

AU - Utsugisawa, Kimiaki

AU - Suzuki, Shigeaki

AU - Masuda, Masayuki

AU - Shimizu, Yuko

AU - Utsumi, Hiroya

AU - Uchiyama, Shinichiro

AU - Suzuki, Norihiro

PY - 2011/7

Y1 - 2011/7

N2 - Introduction. When treating ocular myasthenia gravis (MG), the risk/benefit profile of corticosteroids is unclear, and acetylcholinesterase inhibitors are not very effective. We examined the efficacy of topical naphazoline in the treatment of myasthenic blepharoptosis. Methods. Sixty MG patients with blepharoptosis (32 with ocular symptoms only and 28 with mild generalized symptoms) were enrolled in a multicenter open trial of topical naphazoline. The effects were reported by patients via a questionnaire and were also confirmed for each patient at the clinic. Results. Among 70 eyes of 60 patients, 20 eyes (28.6%) of 17 patients (28.3%) exhibited a marked response (full eye opening), and 24 eyes (34.3%) of 20 patients (33.3%) showed a good response (adequate but incomplete eye opening). Topical naphazoline was evaluated as useful in the treatment of myasthenic blepharoptosis by >70% of the patients. Conclusions. Topical naphazoline was found to be an effective supplementary symptomatic treatment for myasthenic blepharoptosis.

AB - Introduction. When treating ocular myasthenia gravis (MG), the risk/benefit profile of corticosteroids is unclear, and acetylcholinesterase inhibitors are not very effective. We examined the efficacy of topical naphazoline in the treatment of myasthenic blepharoptosis. Methods. Sixty MG patients with blepharoptosis (32 with ocular symptoms only and 28 with mild generalized symptoms) were enrolled in a multicenter open trial of topical naphazoline. The effects were reported by patients via a questionnaire and were also confirmed for each patient at the clinic. Results. Among 70 eyes of 60 patients, 20 eyes (28.6%) of 17 patients (28.3%) exhibited a marked response (full eye opening), and 24 eyes (34.3%) of 20 patients (33.3%) showed a good response (adequate but incomplete eye opening). Topical naphazoline was evaluated as useful in the treatment of myasthenic blepharoptosis by >70% of the patients. Conclusions. Topical naphazoline was found to be an effective supplementary symptomatic treatment for myasthenic blepharoptosis.

KW - Blepharoptosis

KW - Eyewash

KW - Myasthenia gravis

KW - Naphazoline

KW - Open trial

UR - http://www.scopus.com/inward/record.url?scp=79959285856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959285856&partnerID=8YFLogxK

U2 - 10.1002/mus.22002

DO - 10.1002/mus.22002

M3 - Article

C2 - 21491460

AN - SCOPUS:79959285856

VL - 44

SP - 41

EP - 44

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 1

ER -